Related content

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

By Smorenburg C.H.   Bontenbal M.   Seynaeve C.   Zuylen C.v.   Heus G.d.   Verweij J.   Wit R.d.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 1, 2001-03 ,pp. : 83-87

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Study of Continuous Infusion 5-Fluorouracil (5-FU) with Epirubicin and Cisplatin in Metastatic, Hormone-resistant Prostate Cancer: an Active New Regimen

By Chao D.   von Schlippe M.   Harland S.J.  

European Journal of Cancer, Vol. 33, Iss. 8, 1997-07 ,pp. : 1230-1233

Elsevier

Access to resources Recommend Favorite

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer

By Park Keon   Ahn Jin   Park Young   Lee Jeeyun   Kang Jung   Park Joon   Lim Ho   Im Young-Hyuck   Kang Won   Park Keunchil   Lee Soon  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 17-21

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer

By                            

Oncology Reports, Vol. 27, Iss. 3, 2012-01 ,pp. : 657-663

Spandidos Publications

Access to resources Recommend Favorite

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane

By Suzuki Yasuhiro   Saeki Toshiaki   Aogi Kenjiro   Toi Masakazu   Fujii Hirofumi   Inoue Kenichi   Watanabe Toru   Fujiwara Yasuhiro   Ito Yoshinori   Takatsuka Yuichi   Iwata Hiroji   Arioka Hitoshi   Tokuda Yutaka  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 590-597

Springer Publishing Company

Access to resources Recommend Favorite